Are Abdominal Aortic Aneurysm Screening Programs Overstated?

With the remarkable drop in tobacco use across the world, also dropped mortality associated to abdominal aorta aneurysm rupture (AAA). All AAA screening programs have been designed decades ago, when the risk was higher. This is why we might need to rethink these programs, or at least design new randomized controlled studies to pave the way.

This Swedish analysis looked into AAA related mortality in the last years and compared men from regions that had access to adequate screening programs and those who did not. Its outcomes raise the question: is it worth to keep systematically screening for this disease?

 

The Swedish program was based on randomized and controlled studies carried out in the 80s and 90s, when the incidence of this disease was higher. Today, some studies account for a 70% drop in AAA incidence, which could be explained by a drop in tobacco use. With the drop in AAA incidence, we could expect a drop in the net clinical benefit of screening programs, or at least a change in their cost benefit ratio.


Read also: Urgent/Emergent TAVR: A Valid Option.


The present study, recently published in the Lancet, looked into AAA related mortality between 1987 and 2015, with a drop from 36 to just 10 deaths every 100,000 men between 65 and 74 years of age.

 

It also compared mortality between regions that had access to these screening programs and those that did not. Mortality decrease after a 6 year follow up saw no changes in the screening group (OR 0.76; CI 95% 0.38–1.51). With today’s figures, for every 10,000 mean actively screened for this disease, we can expect 2 deaths.

 

In the sample group, there obviously were more AAA cases, which lead to 19 programmed interventions every 10,000 hombres, though 49 cases were overdiagnosed.


Read also: Real-Life Functional Assessment of Coronary Stenosis: We Are Yet to Convert to It.


Study limitations include no information on the size or the type or aneurysms and that not all countries had successful stop-smoking programs, so reduced AAA incidence in Sweden does not necessarily mean a global reduction of this disease.

 

Original titleBenefits and harms of screening men for abdominal aortic aneurysm in Sweden: a registry-based cohort study.

Reference: Johansson M et al. Lancet. 2018;391:2441-2447.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...